Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances
Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Khan, Imran [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering - Liu, Yansheng ELSEVIER, 2020, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:54 ; year:2021 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.cocis.2021.101452 |
|---|
| Katalog-ID: |
ELV054722799 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV054722799 | ||
| 003 | DE-627 | ||
| 005 | 20230626040646.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cocis.2021.101452 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001465.pica |
| 035 | |a (DE-627)ELV054722799 | ||
| 035 | |a (ELSEVIER)S1359-0294(21)00036-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 51.79 |2 bkl | ||
| 084 | |a 35.48 |2 bkl | ||
| 100 | 1 | |a Khan, Imran |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances |
| 264 | 1 | |c 2021transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. | ||
| 520 | |a Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. | ||
| 650 | 7 | |a Molecular farming |2 Elsevier | |
| 650 | 7 | |a Autoimmune diseases |2 Elsevier | |
| 650 | 7 | |a Oral tolerance |2 Elsevier | |
| 650 | 7 | |a Transplastomic plants |2 Elsevier | |
| 650 | 7 | |a Chloroplast |2 Elsevier | |
| 650 | 7 | |a Protein drugs |2 Elsevier | |
| 650 | 7 | |a Metabolic disorders |2 Elsevier | |
| 700 | 1 | |a Daniell, Henry |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Liu, Yansheng ELSEVIER |t Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |d 2020 |g Amsterdam [u.a.] |w (DE-627)ELV003906671 |
| 773 | 1 | 8 | |g volume:54 |g year:2021 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.cocis.2021.101452 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 51.79 |j Sonstige Werkstoffe |q VZ |
| 936 | b | k | |a 35.48 |j Sonstige anorganische Elemente und ihre Verbindungen |q VZ |
| 951 | |a AR | ||
| 952 | |d 54 |j 2021 |h 0 | ||
| author_variant |
i k ik |
|---|---|
| matchkey_str |
khanimrandaniellhenry:2021----:rleieyfhrpuipoenbonasltdnlnclsrci |
| hierarchy_sort_str |
2021transfer abstract |
| bklnumber |
51.79 35.48 |
| publishDate |
2021 |
| allfields |
10.1016/j.cocis.2021.101452 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001465.pica (DE-627)ELV054722799 (ELSEVIER)S1359-0294(21)00036-4 DE-627 ger DE-627 rakwb eng 540 VZ 51.79 bkl 35.48 bkl Khan, Imran verfasserin aut Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. Molecular farming Elsevier Autoimmune diseases Elsevier Oral tolerance Elsevier Transplastomic plants Elsevier Chloroplast Elsevier Protein drugs Elsevier Metabolic disorders Elsevier Daniell, Henry oth Enthalten in Elsevier Science Liu, Yansheng ELSEVIER Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering 2020 Amsterdam [u.a.] (DE-627)ELV003906671 volume:54 year:2021 pages:0 https://doi.org/10.1016/j.cocis.2021.101452 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 51.79 Sonstige Werkstoffe VZ 35.48 Sonstige anorganische Elemente und ihre Verbindungen VZ AR 54 2021 0 |
| spelling |
10.1016/j.cocis.2021.101452 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001465.pica (DE-627)ELV054722799 (ELSEVIER)S1359-0294(21)00036-4 DE-627 ger DE-627 rakwb eng 540 VZ 51.79 bkl 35.48 bkl Khan, Imran verfasserin aut Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. Molecular farming Elsevier Autoimmune diseases Elsevier Oral tolerance Elsevier Transplastomic plants Elsevier Chloroplast Elsevier Protein drugs Elsevier Metabolic disorders Elsevier Daniell, Henry oth Enthalten in Elsevier Science Liu, Yansheng ELSEVIER Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering 2020 Amsterdam [u.a.] (DE-627)ELV003906671 volume:54 year:2021 pages:0 https://doi.org/10.1016/j.cocis.2021.101452 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 51.79 Sonstige Werkstoffe VZ 35.48 Sonstige anorganische Elemente und ihre Verbindungen VZ AR 54 2021 0 |
| allfields_unstemmed |
10.1016/j.cocis.2021.101452 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001465.pica (DE-627)ELV054722799 (ELSEVIER)S1359-0294(21)00036-4 DE-627 ger DE-627 rakwb eng 540 VZ 51.79 bkl 35.48 bkl Khan, Imran verfasserin aut Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. Molecular farming Elsevier Autoimmune diseases Elsevier Oral tolerance Elsevier Transplastomic plants Elsevier Chloroplast Elsevier Protein drugs Elsevier Metabolic disorders Elsevier Daniell, Henry oth Enthalten in Elsevier Science Liu, Yansheng ELSEVIER Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering 2020 Amsterdam [u.a.] (DE-627)ELV003906671 volume:54 year:2021 pages:0 https://doi.org/10.1016/j.cocis.2021.101452 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 51.79 Sonstige Werkstoffe VZ 35.48 Sonstige anorganische Elemente und ihre Verbindungen VZ AR 54 2021 0 |
| allfieldsGer |
10.1016/j.cocis.2021.101452 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001465.pica (DE-627)ELV054722799 (ELSEVIER)S1359-0294(21)00036-4 DE-627 ger DE-627 rakwb eng 540 VZ 51.79 bkl 35.48 bkl Khan, Imran verfasserin aut Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. Molecular farming Elsevier Autoimmune diseases Elsevier Oral tolerance Elsevier Transplastomic plants Elsevier Chloroplast Elsevier Protein drugs Elsevier Metabolic disorders Elsevier Daniell, Henry oth Enthalten in Elsevier Science Liu, Yansheng ELSEVIER Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering 2020 Amsterdam [u.a.] (DE-627)ELV003906671 volume:54 year:2021 pages:0 https://doi.org/10.1016/j.cocis.2021.101452 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 51.79 Sonstige Werkstoffe VZ 35.48 Sonstige anorganische Elemente und ihre Verbindungen VZ AR 54 2021 0 |
| allfieldsSound |
10.1016/j.cocis.2021.101452 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001465.pica (DE-627)ELV054722799 (ELSEVIER)S1359-0294(21)00036-4 DE-627 ger DE-627 rakwb eng 540 VZ 51.79 bkl 35.48 bkl Khan, Imran verfasserin aut Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances 2021transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. Molecular farming Elsevier Autoimmune diseases Elsevier Oral tolerance Elsevier Transplastomic plants Elsevier Chloroplast Elsevier Protein drugs Elsevier Metabolic disorders Elsevier Daniell, Henry oth Enthalten in Elsevier Science Liu, Yansheng ELSEVIER Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering 2020 Amsterdam [u.a.] (DE-627)ELV003906671 volume:54 year:2021 pages:0 https://doi.org/10.1016/j.cocis.2021.101452 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 51.79 Sonstige Werkstoffe VZ 35.48 Sonstige anorganische Elemente und ihre Verbindungen VZ AR 54 2021 0 |
| language |
English |
| source |
Enthalten in Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering Amsterdam [u.a.] volume:54 year:2021 pages:0 |
| sourceStr |
Enthalten in Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering Amsterdam [u.a.] volume:54 year:2021 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Sonstige Werkstoffe Sonstige anorganische Elemente und ihre Verbindungen |
| institution |
findex.gbv.de |
| topic_facet |
Molecular farming Autoimmune diseases Oral tolerance Transplastomic plants Chloroplast Protein drugs Metabolic disorders |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |
| authorswithroles_txt_mv |
Khan, Imran @@aut@@ Daniell, Henry @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003906671 |
| dewey-sort |
3540 |
| id |
ELV054722799 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV054722799</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626040646.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cocis.2021.101452</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001465.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV054722799</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-0294(21)00036-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.79</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.48</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Khan, Imran</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molecular farming</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Autoimmune diseases</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oral tolerance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Transplastomic plants</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chloroplast</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Protein drugs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Metabolic disorders</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Daniell, Henry</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Liu, Yansheng ELSEVIER</subfield><subfield code="t">Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV003906671</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:54</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cocis.2021.101452</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.79</subfield><subfield code="j">Sonstige Werkstoffe</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.48</subfield><subfield code="j">Sonstige anorganische Elemente und ihre Verbindungen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">54</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Khan, Imran |
| spellingShingle |
Khan, Imran ddc 540 bkl 51.79 bkl 35.48 Elsevier Molecular farming Elsevier Autoimmune diseases Elsevier Oral tolerance Elsevier Transplastomic plants Elsevier Chloroplast Elsevier Protein drugs Elsevier Metabolic disorders Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances |
| authorStr |
Khan, Imran |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003906671 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 VZ 51.79 bkl 35.48 bkl Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances Molecular farming Elsevier Autoimmune diseases Elsevier Oral tolerance Elsevier Transplastomic plants Elsevier Chloroplast Elsevier Protein drugs Elsevier Metabolic disorders Elsevier |
| topic |
ddc 540 bkl 51.79 bkl 35.48 Elsevier Molecular farming Elsevier Autoimmune diseases Elsevier Oral tolerance Elsevier Transplastomic plants Elsevier Chloroplast Elsevier Protein drugs Elsevier Metabolic disorders |
| topic_unstemmed |
ddc 540 bkl 51.79 bkl 35.48 Elsevier Molecular farming Elsevier Autoimmune diseases Elsevier Oral tolerance Elsevier Transplastomic plants Elsevier Chloroplast Elsevier Protein drugs Elsevier Metabolic disorders |
| topic_browse |
ddc 540 bkl 51.79 bkl 35.48 Elsevier Molecular farming Elsevier Autoimmune diseases Elsevier Oral tolerance Elsevier Transplastomic plants Elsevier Chloroplast Elsevier Protein drugs Elsevier Metabolic disorders |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
h d hd |
| hierarchy_parent_title |
Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |
| hierarchy_parent_id |
ELV003906671 |
| dewey-tens |
540 - Chemistry |
| hierarchy_top_title |
Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003906671 |
| title |
Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances |
| ctrlnum |
(DE-627)ELV054722799 (ELSEVIER)S1359-0294(21)00036-4 |
| title_full |
Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances |
| author_sort |
Khan, Imran |
| journal |
Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |
| journalStr |
Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Khan, Imran |
| container_volume |
54 |
| class |
540 VZ 51.79 bkl 35.48 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Khan, Imran |
| doi_str_mv |
10.1016/j.cocis.2021.101452 |
| dewey-full |
540 |
| title_sort |
oral delivery of therapeutic proteins bioencapsulated in plant cells: preclinical and clinical advances |
| title_auth |
Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances |
| abstract |
Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. |
| abstractGer |
Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. |
| abstract_unstemmed |
Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances |
| url |
https://doi.org/10.1016/j.cocis.2021.101452 |
| remote_bool |
true |
| author2 |
Daniell, Henry |
| author2Str |
Daniell, Henry |
| ppnlink |
ELV003906671 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.cocis.2021.101452 |
| up_date |
2024-07-06T22:31:14.153Z |
| _version_ |
1803870613436104704 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV054722799</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626040646.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cocis.2021.101452</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001465.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV054722799</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-0294(21)00036-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.79</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.48</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Khan, Imran</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oral delivery of protein drugs (PDs) made in plant cells could revolutionize current approaches to their production and delivery. Expression of PDs reduces their production cost by elimination of prohibitively expensive fermentation, purification, cold transportation/storage, and sterile injections and increases their shelf life for several years. The ability of plant cell wall to protect PDs from digestive acids/enzymes, commensal bacteria to release PDs in gut lumen after lysis of plant cell wall, and the role of gut-associated lymphoid tissue in inducing tolerance facilitate prevention or treatment of allergic, autoimmune diseases or antidrug antibody responses. The delivery of functional proteins facilitates treatment of inherited or metabolic disorders. Recent advances in making PDs free of antibiotic resistance genes in edible plant cells, long-term storage at ambient temperature maintaining their efficacy, production in Current Good Manufacturing Practice (cGMP) facilities, Investigational New Drug (IND)-enabling studies for clinical advancement, and Food and Drug Administration approval of orally delivered PDs augur well for advancing this novel drug delivery platform technology.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molecular farming</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Autoimmune diseases</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oral tolerance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Transplastomic plants</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chloroplast</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Protein drugs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Metabolic disorders</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Daniell, Henry</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Liu, Yansheng ELSEVIER</subfield><subfield code="t">Quantitative analysis of the defects in CVD grown graphene by plasmon-enhanced Raman scattering</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV003906671</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:54</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cocis.2021.101452</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.79</subfield><subfield code="j">Sonstige Werkstoffe</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.48</subfield><subfield code="j">Sonstige anorganische Elemente und ihre Verbindungen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">54</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.398698 |